The Canadian Drug Expert Committee (CDEC) has recommended that fluticasone furoate/vilanterol (FF/V) be listed for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations, if the following clinical criteria are met: 

• Moderate to severe COPD as defined by spirometry
• Inadequate response to a long-acting bronchodilator (long-acting beta-2 agonist [LABA]/long-acting muscarinic antagonist [LAMA]) or experiencing exacerbations more than once per year while on a long-acting bronchodilator

For more details, go to: http://www.cadth.ca/media/cdr/complete/cdr_complete_breo_ellipta_august_20_2014.pdf